Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363467 · ClinicalTrials.gov registry record · NA
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00363467 is a NA study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 3 participants.
The verdict
NCT00363467, a NA study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body weight is obtained, or up to a maximum of 5 days. Conditioning/Preparative therapy will follow PBSC collection for up to 30 days with Busulfan IV daily x 4 days; subsequent doses will be adjusted based on pharmacokinetic (plasma level)monitoring. Following 1 day of rest, stem cell reinfusion will begin with supportive care. During follow-up, patients will be monitored out to 730 days.
Interventions
- DRUG Busulfan
- DRUG G-CSF
- DRUG Leukapheresis
- PROCEDURE Stem cell reinfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363467
The ClinicalTrials.gov registry entry for NCT00363467 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Busulfan is the first listed.
NCT00363467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363467 about?
NCT00363467 is a clinical study titled "Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation". During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body weight is obtained, or up to a maximum of 5 days. Conditioning/Preparative...
What is the current status of trial NCT00363467?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2006-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00363467?
The interventions under investigation include: Busulfan (DRUG), G-CSF (DRUG), Leukapheresis (DRUG), Stem cell reinfusion (PROCEDURE).
Who is sponsoring clinical trial NCT00363467?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.